Browsing by Subject "bispecific antibody"
Now showing 1 - 1 of 1
- Results Per Page
- Sort Options
Item Open Access A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma.(Oncoimmunology, 2013-12) Chandramohan, Vidyalakshmi; Bigner, Darell DBoth the amplification of the gene coding for wild-type (wt) epidermal growth factor receptor (EGFR) and the overexpression of the EGFR deletion mutant, commonly known as EGFRvIII, are hallmarks of glioblastoma. We have recently reported a novel, recombinant immunotoxin, D2C7-(scdsFv)-PE38KDEL, that targets both wt EGFR and EGFRvIII, exhibiting potent antineoplastic effects against established murine gliomas.